Schwab Charles Investment Management Inc. Trims Position in Achillion Pharmaceuticals, Inc. (ACHN)

Schwab Charles Investment Management Inc. decreased its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 6.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 658,344 shares of the biopharmaceutical company’s stock after selling 42,504 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.48% of Achillion Pharmaceuticals worth $1,864,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter valued at $135,000. Element Capital Management LLC purchased a new position in Achillion Pharmaceuticals during the 1st quarter worth $163,000. New York State Common Retirement Fund raised its position in Achillion Pharmaceuticals by 24.1% during the 1st quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 28,500 shares during the last quarter. A.R.T. Advisors LLC raised its position in Achillion Pharmaceuticals by 39.7% during the 1st quarter. A.R.T. Advisors LLC now owns 185,913 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 52,800 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Achillion Pharmaceuticals by 11.9% during the 1st quarter. California State Teachers Retirement System now owns 206,482 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 22,017 shares during the last quarter. Hedge funds and other institutional investors own 78.36% of the company’s stock.

A number of brokerages have commented on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 25th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $4.38.

Shares of Achillion Pharmaceuticals stock opened at $3.13 on Friday. The firm has a market cap of $510.00 million, a price-to-earnings ratio of -5.05 and a beta of 1.27. Achillion Pharmaceuticals, Inc. has a one year low of $2.33 and a one year high of $4.63.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. As a group, sell-side analysts expect that Achillion Pharmaceuticals, Inc. will post -0.52 earnings per share for the current year.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

See Also: Earnings Per Share (EPS)

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply